Novavax Inc. (NASDAQ:NVAX) went down by -3.91% from its latest closing price compared to the recent 1-year high of $331.68. The company’s stock price has collected -0.89% of loss in the last five trading sessions. Press Release reported on 04/05/21 that Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover
Is It Worth Investing in Novavax Inc. (NASDAQ :NVAX) Right Now?
Plus, the 36-month beta value for NVAX is at 1.47. Opinions of the stock are interesting as 5 analysts out of 5 who provided ratings for Novavax Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $323.00, which is $128.98 above the current price. NVAX currently public float of 62.53M and currently shorts hold a 7.91% ratio of that float. Today, the average trading volume of NVAX was 4.41M shares.
NVAX’s Market Performance
NVAX stocks went down by -0.89% for the week, with a monthly jump of 8.80% and a quarterly performance of 47.77%, while its annual performance rate touched 966.89%. The volatility ratio for the week stands at 6.12% while the volatility levels for the past 30 days are set at 9.06% for Novavax Inc.. The simple moving average for the period of the last 20 days is -12.62% for NVAX stocks with a simple moving average of 23.12% for the last 200 days.
Analysts’ Opinion of NVAX
Many brokerage firms have already submitted their reports for NVAX stocks, with Jefferies repeating the rating for NVAX by listing it as a “Buy.” The predicted price for NVAX in the upcoming period, according to Jefferies is $200 based on the research report published on December 14th of the previous year 2020.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see NVAX reach a price target of $290, previously predicting the price at $132. The rating they have provided for NVAX stocks is “Buy” according to the report published on August 06th, 2020.
JP Morgan gave a rating of “Overweight” to NVAX, setting the target price at $275 in the report published on August 05th of the previous year.
NVAX Trading at -21.69% from the 50-Day Moving Average
After a stumble in the market that brought NVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.21% of loss for the given period.
Volatility was left at 9.06%, however, over the last 30 days, the volatility rate increased by 6.12%, as shares surge +1.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +30.66% upper at present.
During the last 5 trading sessions, NVAX fell by -0.89%, which changed the moving average for the period of 200-days by +165.28% in comparison to the 20-day moving average, which settled at $196.66. In addition, Novavax Inc. saw 54.04% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at NVAX starting from Trizzino John, who sale 191 shares at the price of $178.03 back on Apr 07. After this action, Trizzino John now owns 287 shares of Novavax Inc., valued at $34,004 using the latest closing price.
Trizzino John, the EVP, Chief Commercial Officer of Novavax Inc., sale 3,021 shares at $190.10 during a trade that took place back on Apr 05, which means that Trizzino John is holding 287 shares at $574,292 based on the most recent closing price.
Stock Fundamentals for NVAX
Current profitability levels for the company are sitting at:
- -87.05 for the present operating margin
The net margin for Novavax Inc. stands at -87.94. The total capital return value is set at -65.98, while invested capital returns managed to touch -73.12. Equity return is now at value -187.10, with -44.20 for asset returns.
Based on Novavax Inc. (NVAX), the company’s capital structure generated 76.83 points at debt to equity in total, while total debt to capital is 43.45. Total debt to assets is 30.45, with long-term debt to equity ratio resting at 59.35. Finally, the long-term debt to capital ratio is 33.56.
When we switch over and look at the enterprise to sales, we see a ratio of 12.82, with the company’s debt to enterprise value settled at 0.08. The receivables turnover for the company is 3.53 and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.15.